Latest On Brainstorm Cell Therapeutics Inc (BCLI):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-25 04:14 EST | News | Brainstorm Cell COO Setboun to leave company - filing | N/A |  |
| 2023-05-15 21:20 EST | News | Brainstorm Cell Therapeutics Inc. (BCLI) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-15 07:26 EST | News | BrainStorm Cell Therapeutics GAAP EPS of -$0.14 beats by $0.03 | N/A | |
| 2023-03-31 01:41 EST | News | BrainStorm Cell Therapeutics GAAP EPS of -$0.66 misses by $0.52 | N/A | |
| 2023-03-31 01:41 EST | News | BrainStorm: Upcoming AdCom Meeting For NurOwn For ALS Could Be Start Of Major Turnaround | N/A | |
| 2023-03-31 01:41 EST | News | Brainstorm stock pares off gains amid FY22 results seeing cash decline | N/A | |
| 2023-03-31 01:41 EST | News | Brainstorm Cell Therapeutics Inc. (BCLI) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-27 12:07 EST | News | Brainstorm granted FDA AdCom meeting for ALS therapy | N/A | |
| 2023-01-04 16:48 EST | News | BrainStorm Cell Therapeutics promotes Stacy Lindborg to co-CEO | N/A | |
| 2022-12-27 19:08 EST | News | BrainStorm gets FDA panel meeting to discuss declined filing for ALS drug NurOwn | N/A | |
| 2022-11-14 23:03 EST | News | BrainStorm Cell Therapeutics GAAP EPS of -$0.53 | N/A | |
| 2022-11-14 23:02 EST | News | Brainstorm Cell Therapeutics Inc. (BCLI) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-13 12:13 EST | News | BrainStorm Cell Therapeutics Q3 2022 Earnings Preview | N/A | |
| 2022-11-10 13:33 EST | News | BrainStorm plunges 76% as FDA declines marketing application for ALS therapy | N/A | |
| 2022-08-21 05:36 EST | News | Brainstorm Cell Therapeutics: Upcoming BLA In ALS | N/A | |
| 2022-08-15 11:36 EST | News | BrainStorm Cell Therapeutics GAAP EPS of -$0.34 | N/A | |
| 2022-08-15 11:36 EST | News | BrainStorm to seek FDA approval for ALS therapy despite Phase 3 setback | N/A | |
| 2022-08-15 11:35 EST | News | Brainstorm Cell Therapeutics Inc.'s (BCLI) CEO Chaim Lebovits on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-12 15:29 EST | News | BrainStorm Cell Therapeutics Q2 2022 Earnings Preview | N/A | |
| 2022-05-17 03:49 EST | News | Brainstorm Cell Therapeutics Inc.'s (BCLI) CEO Chaim Lebovits on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-16 08:53 EST | News | BrainStorm Cell Therapeutics GAAP EPS of -$0.15 misses by $0.02 | N/A | |
| 2022-03-28 15:14 EST | News | BrainStorm Cell Therapeutics GAAP EPS of -$0.68 beats by $0.11 | N/A | |
| 2022-03-28 15:13 EST | News | BrainStorm Cell Therapeutics stock falls amid FY21 results | N/A | |
| 2022-03-28 15:13 EST | News | BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-02-15 18:59 EST | News | Brainstorm Cell gets Brazilian patent covering methods of manufacturing NurOwn | N/A | |
| 2021-12-27 09:40 EST | News | FDA authorizes further dosing of BrainStorm Cell's NurOwn under expanded access program | N/A | |
| 2021-11-15 21:19 EST | News | BrainStorm Cell Therapeutics EPS misses by $0.31 | N/A | |
| 2021-11-15 21:18 EST | News | Brainstorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-12 17:24 EST | News | BrainStorm Cell Therapeutics Q3 2021 Earnings Preview | N/A | |
| 2021-10-27 13:54 EST | News | Warning: BCLI is at high risk of performing badly | N/A | |
| 2021-10-07 05:49 EST | News | BCLI is at high risk of performing badly | N/A | |
| 2021-09-27 13:37 EST | News | Warning: BCLI has been downgraded to Very Bearish | N/A | |
| 2021-09-22 22:20 EST | News | Warning: BCLI has been downgraded to Very Bearish. | N/A | |
| 2021-08-05 22:44 EST | News | BrainStorm Cell Therapeutics EPS beats by $0.05 | N/A | |
| 2021-08-05 22:42 EST | News | BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-07-20 21:02 EST | News | Brainstorm Cell Therapeutics: MSC-NTF Cell Therapy Shows Mid-Stage Promise In PMS | N/A | |
| 2021-04-28 10:14 EST | News | BrainStorm Cell Therapeutics Inc.'s (BCLI) CEO Chaim Lebovits on Q1 2021 Results - Earnings Call Transcript | N/A | |
| 2021-04-26 16:44 EST | News | BrainStorm Cell Therapeutics EPS beats by $0.07 | N/A | |
| 2021-04-26 16:44 EST | News | BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q1 2021 Results - Earnings Call Transcript | N/A | |
| 2021-03-24 14:45 EST | News | BrainStorm shares surge 20% on positive NurOwn data in multiple sclerosis | N/A | |
| 2021-03-03 22:40 EST | News | In unusual step, FDA provides additional details on BrainStorm's NurOwn program | N/A | |
| 2021-02-22 17:30 EST | News | BrainStorm shares plunge 25% after FDA feedback on NurOwn program | N/A | |
| 2021-02-10 07:13 EST | Analyst Rating | The Analyst Target Price has decreased from $29 to $17.5. | Neutral | |
| 2021-02-06 03:11 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-05 15:11 EST | Earnings Estimate | An EPS average of -$0.25 is estimated for the quarter ending on March 31, 2021. | Buy | |
| 2021-02-05 15:11 EST | Earnings Estimate | An EPS average of -$0.88 is estimated for the 2022 year. | Sell | |
| 2021-02-05 15:11 EST | Earnings Estimate | An EPS average of -$0.26 is estimated for the quarter ending on June 30, 2021. | Buy | |
| 2021-02-05 04:47 EST | News | Brainstorm Cell Therapeutics Inc.'s (BCLI) CEO Chaim Lebovits on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-02-04 10:11 EST | News | BrainStorm Cell Therapeutics EPS misses by $0.18 | N/A | |
| 2021-01-18 19:50 EST | News | Brainstorm Cell Therapeutics: What's Left After Recent Trial Failure | N/A | |
About Brainstorm Cell Therapeutics Inc (BCLI):
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and in Phase II for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other central nervous system disorders. The company has a partnership with Catalent for the manufacture of NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.
General
- Name Brainstorm Cell Therapeutics Inc
- Symbol BCLI
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 40
- Last Split Factor1:15
- Last Split Date2014-09-16
- Fiscal Year EndDecember
- IPO Date2003-08-28
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.brainstorm-cell.com
View More
Valuation
- Price/Book (Most Recent Quarter) 4.35
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.38
- Next Year EPS Estimate -$0.92
- Return on Assets -69%
- Return on Equity -274%
- Earnings Per Share -$0.88
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 141.46 million
- EBITDA -18323000
- Analyst Target Price $17.5
- Book Value Per Share $1.01
View More
Share Statistics
- Shares Outstanding 35.72 million
- Shares Float 31.54 million
- % Held by Insiders 1978%
- % Held by Institutions 22.78%
- Shares Short 3.93 million
- Shares Short Prior Month 4.22 million
- Short Ratio 2.5
- Short % of Float 13%
- Short % of Shares Outstanding 11%
View More
Technicals
- Beta 0.16
- 52 Week High $17.95
- 52 Week Low $3.1
- 50 Day Moving Average 5.34
- 200 Day Moving Average 8.47
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Brainstorm Cell Therapeutics Inc (BCLI) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Brainstorm Cell Therapeutics Inc (BCLI) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-04 | $N/A | -$0.37 | -$0.20 | -89.74% |
| 2020-09-30 | 2020-10-15 | $N/A | -$0.14 | -$0.26 | 45.1% |
| 2020-06-30 | 2020-08-05 | $N/A | -$0.25 | -$0.26 | 1.96% |
| 2020-03-31 | 2020-05-07 | $N/A | -$0.32 | -$0.22 | -45.45% |
| 2019-12-31 | 2020-02-18 | $N/A | -$0.34 | -$0.20 | -70% |
| 2019-09-30 | 2019-11-14 | $N/A | -$0.25 | -$0.22 | -13.64% |
| 2019-06-30 | 2019-08-13 | $N/A | -$0.23 | -$0.19 | -21.05% |
| 2019-03-31 | 2019-05-10 | $N/A | -$0.24 | -$0.11 | -118.18% |
| 2018-12-31 | 2019-03-29 | $N/A | -$0.27 | -$0.14 | -92.86% |
| 2018-09-30 | 2018-10-29 | $N/A | -$0.15 | -$0.16 | 6.25% |
| 2018-06-30 | 2018-07-23 | $N/A | -$0.16 | -$0.13 | -26.28% |
| 2018-03-31 | 2018-05-14 | $N/A | -$0.12 | -$0.14 | 14.29% |
| 2017-12-31 | 2018-03-08 | $N/A | $0.03 | -$0.09 | 133.33% |
| 2017-09-30 | 2017-10-17 | $N/A | -$0.13 | -$0.16 | 18.75% |
| 2017-06-30 | 2017-08-14 | $N/A | -$0.06 | -$0.13 | 52% |
| 2017-03-31 | 2017-05-15 | $N/A | -$0.10 | -$0.17 | 41.18% |
| 2016-12-31 | 2017-03-29 | $N/A | -$0.04 | -$0.09 | 52.94% |
| 2016-09-30 | 2016-11-14 | $N/A | -$0.09 | -$0.11 | 14.29% |
| 2016-06-30 | 2016-08-11 | $N/A | -$0.05 | -$0.14 | 64.29% |
| 2016-03-31 | 2016-05-10 | $N/A | -$0.10 | -$0.08 | -25% |
| 2015-12-31 | 2016-03-09 | $N/A | -$0.08 | -$0.15 | 46.67% |
| 2015-09-30 | 2015-11-16 | $N/A | -$0.14 | -$0.15 | 6.67% |
| 2015-06-30 | 2015-08-13 | $N/A | -$0.12 | -$0.14 | 14.29% |
| 2015-03-31 | 2015-05-14 | $N/A | -$0.12 | -$0.13 | 7.69% |
| 2014-12-31 | 2015-03-26 | $N/A | -$0.18 | -$0.15 | -20% |
| 2014-09-30 | 2014-11-13 | $N/A | -$0.16 | -$0.20 | 20% |
| 2014-06-30 | 2014-09-03 | $N/A | -$0.16 | ||
| 2014-03-31 | 2014-05-28 | $N/A | -$0.18 | ||
| 2013-12-31 | 2014-02-26 | $N/A | -$0.15 | ||
| 2013-09-30 | 2013-09-30 | $N/A | -$0.10 | ||
| 2013-06-30 | 2013-06-30 | $N/A | -$0.15 | ||
| 2013-03-31 | 2013-03-31 | $N/A | -$0.11 | ||
| 2012-12-31 | 2012-12-31 | $N/A | -$0.06 | ||
| 2012-09-30 | 2012-09-30 | $N/A | -$0.12 | ||
| 2012-06-30 | 2012-06-30 | $N/A | -$0.10 | ||
| 2012-03-31 | 2012-03-31 | $N/A | -$0.10 | ||
| 2011-12-31 | 2011-12-31 | $N/A | -$0.18 | ||
| 2011-09-30 | 2011-09-30 | $N/A | -$0.08 | ||
| 2011-06-30 | 2011-06-30 | $N/A | -$0.14 | ||
| 2011-03-31 | 2011-03-31 | $N/A | -$0.10 | ||
| 2010-12-31 | 2010-12-31 | $N/A | -$0.08 | ||
| 2010-09-30 | 2010-09-30 | $N/A | -$0.12 | ||
| 2010-06-30 | 2010-06-30 | $N/A | -$0.10 | ||
| 2010-03-31 | 2010-03-31 | $N/A | -$0.11 | ||
| 2009-12-31 | 2009-12-31 | -$0.03 | |||
| 2009-09-30 | 2009-09-30 | -$0.15 | |||
| 2009-06-30 | 2009-06-30 | -$0.14 | |||
| 2009-03-31 | 2009-03-31 | -$0.14 | |||
| 2008-09-30 | 2008-09-30 | -$0.21 | |||
| 2008-06-30 | 2008-06-30 | -$0.27 | |||
| 2008-03-31 | 2008-03-31 | -$0.45 | |||
| 2007-12-31 | 2007-12-31 | -$0.75 | |||
| 2007-09-30 | 2007-09-30 | -$0.60 | |||
| 2007-06-30 | 2007-06-30 | -$1.06 | |||
| 2007-03-31 | 2007-03-31 | -$1.06 | |||
| 2005-03-31 | 2005-03-31 | -$0.45 | |||
| 2004-12-31 | 2004-12-31 | -$12.31 | |||
| 2004-09-30 | 2004-09-30 | -$1.52 | |||
| 2004-06-30 | 2004-06-30 | $0.03 | |||
| 2004-03-31 | 2004-03-31 | -$0.03 | |||
| 2003-12-31 | 2003-12-31 | -$0.01 | |||
| 2003-09-30 | 2003-09-30 | -$0.01 | |||
| 2003-06-30 | 2003-06-30 | -$0.01 |
Brainstorm Cell Therapeutics Inc (BCLI) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Brainstorm Cell Therapeutics Inc (BCLI) Chart:
Brainstorm Cell Therapeutics Inc (BCLI) News:
Below you will find a list of latest news for Brainstorm Cell Therapeutics Inc (BCLI) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Brainstorm Cell Therapeutics Inc (BCLI) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-04-19 | 0.5 | 0.01 | CALL | 19 | 329 | 480.35 | TRUE | -0.07 | -0.88 |
| 2024-04-19 | 1 | 0.01 | CALL | 0 | 1125 | 0 | FALSE | 0 | 0 |
| 2024-04-19 | 1.5 | 0.05 | CALL | 0 | 11 | 0 | FALSE | 0 | 0 |
| 2024-04-19 | 2 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-04-19 | 3 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-04-19 | 4 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-04-19 | 0.5 | 0.01 | PUT | 5 | 948 | 233.73 | FALSE | 0.01 | 0 |
| 2024-04-19 | 1 | 0.47 | PUT | 0 | 13 | 0 | TRUE | 0 | 0 |
| 2024-04-19 | 1.5 | 0.85 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-04-19 | 2 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-04-19 | 3 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-04-19 | 4 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-05-17 | 0.5 | 0.15 | CALL | 0 | 1946 | 221.79 | TRUE | 0 | 0 |
| 2024-05-17 | 1 | 0.05 | CALL | 10 | 1839 | 243.94 | FALSE | 0.05 | 0 |
| 2024-05-17 | 1.5 | 0.05 | CALL | 0 | 12 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2 | 0.05 | CALL | 0 | 125 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 3 | 0.02 | CALL | 0 | 40 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 4 | 0.05 | CALL | 0 | 2 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0.68 | CALL | 0 | 40 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 0.5 | 0.11 | PUT | 0 | 113 | 208.78 | FALSE | 0 | 0 |
| 2024-05-17 | 1 | 0.4 | PUT | 0 | 120 | 176.14 | TRUE | 0 | 0 |
| 2024-05-17 | 1.5 | 0 | PUT | 0 | 0 | 248.83 | TRUE | 0 | 0 |
| 2024-05-17 | 2 | 0 | PUT | 0 | 0 | 626.79 | TRUE | 0 | 0 |
| 2024-05-17 | 3 | 0 | PUT | 0 | 0 | 483.18 | TRUE | 0 | 0 |
| 2024-05-17 | 4 | 0 | PUT | 0 | 0 | 476.28 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 0 | PUT | 0 | 0 | 613.44 | TRUE | 0 | 0 |
| 2024-08-16 | 0.5 | 0.3 | CALL | 0 | 1086 | 312.39 | TRUE | 0 | 0 |
| 2024-08-16 | 1 | 0.14 | CALL | 0 | 481 | 161.67 | FALSE | 0 | 0 |
| 2024-08-16 | 1.5 | 0.05 | CALL | 5 | 166 | 156.74 | FALSE | 0 | 0 |
| 2024-08-16 | 2 | 0.05 | CALL | 0 | 33 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 3 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 4 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 0.5 | 0.23 | PUT | 0 | 8 | 199.41 | FALSE | 0 | 0 |
| 2024-08-16 | 1 | 0.56 | PUT | 0 | 2 | 165.26 | TRUE | 0 | 0 |
| 2024-08-16 | 1.5 | 1.05 | PUT | 3 | 0 | 209.71 | TRUE | 1.05 | 0 |
| 2024-08-16 | 2 | 0 | PUT | 0 | 0 | 162.44 | TRUE | 0 | 0 |
| 2024-08-16 | 3 | 0 | PUT | 0 | 0 | 231.09 | TRUE | 0 | 0 |
| 2024-08-16 | 4 | 0 | PUT | 0 | 0 | 258.3 | TRUE | 0 | 0 |
| 2024-11-15 | 0.5 | 0.3 | CALL | 0 | 209 | 0 | TRUE | 0 | 0 |
| 2024-11-15 | 1 | 0.25 | CALL | 0 | 821 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 1.5 | 0.15 | CALL | 40 | 347 | 182.32 | FALSE | 0.15 | 0 |
| 2024-11-15 | 2 | 0.12 | CALL | 0 | 21 | 382.09 | FALSE | 0 | 0 |
| 2024-11-15 | 3 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 4 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 0.5 | 0.2 | PUT | 0 | 1152 | 192.97 | FALSE | 0 | 0 |
| 2024-11-15 | 1 | 0.56 | PUT | 0 | 20 | 175.55 | TRUE | 0 | 0 |
| 2024-11-15 | 1.5 | 0 | PUT | 0 | 1 | 164.73 | TRUE | 0 | 0 |
| 2024-11-15 | 2 | 0 | PUT | 0 | 0 | 171.79 | TRUE | 0 | 0 |
| 2024-11-15 | 3 | 0 | PUT | 0 | 0 | 162.66 | TRUE | 0 | 0 |
| 2024-11-15 | 4 | 0 | PUT | 0 | 0 | 208.46 | TRUE | 0 | 0 |
Latest BCLI Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 1:52 PM EST | 200 | $2.92 |
| Jun 13, 2022 7:54 PM EST | 6 | $2.93 |
Brainstorm Cell Therapeutics Inc (BCLI) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-26 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1137883/000110465920077518/0001104659-20-077518-index.htm |
| 2018-06-19 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1137883/000000000018018857/0000000000-18-018857-index.htm |
| 2018-07-06 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1137883/000000000018020759/0000000000-18-020759-index.htm |
| 2019-08-22 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1137883/000000000019012750/0000000000-19-012750-index.htm |
| 2019-10-25 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1137883/000110465919056570/0001104659-19-056570-index.htm |
| 2019-11-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1137883/000110465919063577/0001104659-19-063577-index.htm |
| 2019-12-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1137883/000110465919071889/0001104659-19-071889-index.htm |
| 2019-12-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465919076289/0001104659-19-076289-index.htm |
| 2019-12-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465919076290/0001104659-19-076290-index.htm |
| 2019-12-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465919076291/0001104659-19-076291-index.htm |
| 2020-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465920021981/0001104659-20-021981-index.htm |
| 2020-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465920021982/0001104659-20-021982-index.htm |
| 2020-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465920021983/0001104659-20-021983-index.htm |
| 2020-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465920021984/0001104659-20-021984-index.htm |
| 2020-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465920021985/0001104659-20-021985-index.htm |
| 2020-02-18 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1137883/000110465920022244/0001104659-20-022244-index.htm |
| 2020-03-06 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1137883/000110465920030108/0001104659-20-030108-index.htm |
| 2020-03-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1137883/000110465920030109/0001104659-20-030109-index.htm |
| 2020-03-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465920030195/0001104659-20-030195-index.htm |
| 2020-03-06 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1137883/000110465920030254/0001104659-20-030254-index.htm |
| 2020-03-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1137883/000110465920030256/0001104659-20-030256-index.htm |
| 2020-03-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1137883/000110465920033201/0001104659-20-033201-index.htm |
| 2020-03-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465920033203/0001104659-20-033203-index.htm |
| 2020-03-18 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1137883/000110465920034925/0001104659-20-034925-index.htm |
| 2020-03-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1137883/000110465920040839/0001104659-20-040839-index.htm |
| 2020-04-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1137883/000110465920043197/0001104659-20-043197-index.htm |
| 2020-04-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465920044266/0001104659-20-044266-index.htm |
| 2020-04-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465920044267/0001104659-20-044267-index.htm |
| 2020-04-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465920044269/0001104659-20-044269-index.htm |
| 2020-04-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465920044270/0001104659-20-044270-index.htm |
| 2020-04-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465920044271/0001104659-20-044271-index.htm |
| 2020-04-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465920044272/0001104659-20-044272-index.htm |
| 2020-04-08 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1137883/000110465920044387/0001104659-20-044387-index.htm |
| 2020-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1137883/000110465920057690/0001104659-20-057690-index.htm |
| 2020-06-01 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465920068499/0001104659-20-068499-index.htm |
| 2020-06-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465920068501/0001104659-20-068501-index.htm |
| 2020-06-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1137883/000110465920077510/0001104659-20-077510-index.htm |
| 2020-06-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465920077512/0001104659-20-077512-index.htm |
| 2020-06-26 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1137883/000110465920077514/0001104659-20-077514-index.htm |
| 2020-06-26 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1137883/000110465920077518/0001104659-20-077518-index.htm |
| 2020-07-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465920084119/0001104659-20-084119-index.htm |
| 2020-07-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465920084123/0001104659-20-084123-index.htm |
| 2020-07-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465920084127/0001104659-20-084127-index.htm |
| 2020-07-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465920089158/0001104659-20-089158-index.htm |
| 2020-08-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1137883/000110465920090549/0001104659-20-090549-index.htm |
| 2020-08-10 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1137883/000110465920092037/0001104659-20-092037-index.htm |
| 2020-09-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1137883/000110465920102224/0001104659-20-102224-index.htm |
| 2020-09-10 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465920103937/0001104659-20-103937-index.htm |
| 2020-09-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000110465920103943/0001104659-20-103943-index.htm |
| 2020-09-25 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1137883/000110465920108908/0001104659-20-108908-index.htm |
| 2020-09-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1137883/000110465920108914/0001104659-20-108914-index.htm |
| 2020-10-01 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/0001104659-20-111107-index.htm |
| 2020-10-15 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1137883/000110465920115097/0001104659-20-115097-index.htm |
| 2020-10-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1137883/000110465920115102/0001104659-20-115102-index.htm |
| 2020-10-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1137883/000110465920118343/0001104659-20-118343-index.htm |
| 2017-07-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420417038410/0001144204-17-038410-index.htm |
| 2017-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1137883/000114420417043149/0001144204-17-043149-index.htm |
| 2017-08-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420417044724/0001144204-17-044724-index.htm |
| 2017-08-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420417046175/0001144204-17-046175-index.htm |
| 2017-09-14 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1137883/000114420417048051/0001144204-17-048051-index.htm |
| 2017-10-17 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1137883/000114420417052741/0001144204-17-052741-index.htm |
| 2017-11-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1137883/000114420417056236/0001144204-17-056236-index.htm |
| 2017-11-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1137883/000114420417058394/0001144204-17-058394-index.htm |
| 2017-11-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420417058397/0001144204-17-058397-index.htm |
| 2017-11-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420417058398/0001144204-17-058398-index.htm |
| 2017-11-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420417058399/0001144204-17-058399-index.htm |
| 2017-11-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420417058401/0001144204-17-058401-index.htm |
| 2017-11-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420417058402/0001144204-17-058402-index.htm |
| 2017-11-20 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420417060146/0001144204-17-060146-index.htm |
| 2017-11-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420417060168/0001144204-17-060168-index.htm |
| 2018-01-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1137883/000114420418000714/0001144204-18-000714-index.htm |
| 2018-02-05 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420418005726/0001144204-18-005726-index.htm |
| 2018-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420418005728/0001144204-18-005728-index.htm |
| 2018-02-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1137883/000114420418005749/0001144204-18-005749-index.htm |
| 2018-02-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420418011819/0001144204-18-011819-index.htm |
| 2018-03-08 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1137883/000114420418013470/0001144204-18-013470-index.htm |
| 2018-03-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420418015059/0001144204-18-015059-index.htm |
| 2018-03-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420418015580/0001144204-18-015580-index.htm |
| 2018-03-20 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420418015759/0001144204-18-015759-index.htm |
| 2018-03-20 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420418015760/0001144204-18-015760-index.htm |
| 2018-03-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420418016909/0001144204-18-016909-index.htm |
| 2018-03-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420418016910/0001144204-18-016910-index.htm |
| 2018-05-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1137883/000114420418027804/0001144204-18-027804-index.htm |
| 2018-06-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1137883/000114420418033158/0001144204-18-033158-index.htm |
| 2018-06-07 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1137883/000114420418033160/0001144204-18-033160-index.htm |
| 2018-06-08 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1137883/000114420418033428/0001144204-18-033428-index.htm |
| 2018-06-20 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420418034895/0001144204-18-034895-index.htm |
| 2018-06-27 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1137883/000114420418036074/0001144204-18-036074-index.htm |
| 2018-06-29 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1137883/000114420418036682/0001144204-18-036682-index.htm |
| 2018-07-23 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1137883/000114420418039198/0001144204-18-039198-index.htm |
| 2018-07-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420418040473/0001144204-18-040473-index.htm |
| 2018-09-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420418047847/0001144204-18-047847-index.htm |
| 2018-09-21 | S-3/A | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1137883/000114420418050406/0001144204-18-050406-index.htm |
| 2018-09-21 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1137883/000114420418050408/0001144204-18-050408-index.htm |
| 2018-09-28 | 424B1 | Prospectus [Rule 424(b)(1)] | https://www.sec.gov/Archives/edgar/data/1137883/000114420418051595/0001144204-18-051595-index.htm |
| 2018-10-10 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1137883/000114420418053095/0001144204-18-053095-index.htm |
| 2018-10-29 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1137883/000114420418055650/0001144204-18-055650-index.htm |
| 2018-11-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/0001144204-18-062647-index.htm |
| 2018-11-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420418062649/0001144204-18-062649-index.htm |
| 2018-11-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420418062651/0001144204-18-062651-index.htm |
| 2018-11-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420418062653/0001144204-18-062653-index.htm |
| 2018-11-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420418062654/0001144204-18-062654-index.htm |
| 2018-11-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420418062657/0001144204-18-062657-index.htm |
| 2018-12-21 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1137883/000114420418066053/0001144204-18-066053-index.htm |
| 2018-12-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420418066056/0001144204-18-066056-index.htm |
| 2019-01-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420419000986/0001144204-19-000986-index.htm |
| 2019-02-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420419009627/0001144204-19-009627-index.htm |
| 2019-03-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420419013081/0001144204-19-013081-index.htm |
| 2019-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1137883/000114420419013381/0001144204-19-013381-index.htm |
| 2019-03-29 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1137883/000114420419017041/0001144204-19-017041-index.htm |
| 2019-04-01 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1137883/000114420419017368/0001144204-19-017368-index.htm |
| 2019-05-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1137883/000114420419025310/0001144204-19-025310-index.htm |
| 2019-05-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1137883/000114420419025457/0001144204-19-025457-index.htm |
| 2019-06-11 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1137883/000114420419030587/0001144204-19-030587-index.htm |
| 2019-06-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1137883/000114420419030589/0001144204-19-030589-index.htm |
| 2019-07-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1137883/000114420419036265/0001144204-19-036265-index.htm |
| 2019-07-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420419036266/0001144204-19-036266-index.htm |
| 2019-08-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1137883/000114420419037338/0001144204-19-037338-index.htm |
| 2019-08-02 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1137883/000114420419037507/0001144204-19-037507-index.htm |
| 2019-08-09 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420419038938/0001144204-19-038938-index.htm |
| 2019-08-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1137883/000114420419039284/0001144204-19-039284-index.htm |
| 2019-08-16 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1137883/000114420419040442/0001144204-19-040442-index.htm |
| 2019-08-28 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1137883/000114420419042033/0001144204-19-042033-index.htm |
| 2019-08-30 | 424B1 | Prospectus [Rule 424(b)(1)] | https://www.sec.gov/Archives/edgar/data/1137883/000114420419043045/0001144204-19-043045-index.htm |
| 2019-08-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420419043047/0001144204-19-043047-index.htm |
| 2019-09-09 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420419043863/0001144204-19-043863-index.htm |
| 2019-09-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1137883/000114420419043864/0001144204-19-043864-index.htm |
| 2019-09-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1137883/000114420419043866/0001144204-19-043866-index.htm |
| 2019-11-21 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1137883/000133259619000006/0001332596-19-000006-index.htm |
| 2020-05-08 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1137883/000133259620000001/0001332596-20-000001-index.htm |
| 2018-06-29 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1137883/999999999518001675/9999999995-18-001675-index.htm |
| 2018-09-28 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1137883/999999999518002494/9999999995-18-002494-index.htm |
| 2019-08-30 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1137883/999999999519002000/9999999995-19-002000-index.htm |
Brainstorm Cell Therapeutics Inc (BCLI) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Brainstorm Cell Therapeutics Inc (BCLI). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 1978%Institutional Ownership: 2278%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2019-02-01 | Anthony J. Polverino | Director | Buy | 3,501.00 | 10,791.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420419009627/0001144204-19-009627-index.htm | ||
| 2019-03-06 | Ralph Dr. Kern | COO and Chief Medical Officer | Buy | 35,885.00 | 112,655.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420419013081/0001144204-19-013081-index.htm | ||
| 2019-12-24 | Ralph Dr. Kern | COO and Chief Medical Officer | Buy | 3,000.00 | 3.88 | 11,640.00 | 115,655.00 | https://www.sec.gov/Archives/edgar/data/1137883/000110465919076291/0001104659-19-076291-index.htm |
| 2017-11-10 | Chen Schor | Director | Buy | 2,000.00 | 123,558.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420417058397/0001144204-17-058397-index.htm | ||
| 2020-07-26 | Chaim Lebovits | Chief Executive Officer | Buy | 31,185.00 | 124,740.00 | https://www.sec.gov/Archives/edgar/data/1137883/000110465920089158/0001104659-20-089158-index.htm | ||
| 2018-11-30 | Chen Schor | Director | Buy | 2,000.00 | 125,558.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420418062657/0001144204-18-062657-index.htm | ||
| 2019-12-12 | Anthony J. Polverino | Director | Buy | 2,000.00 | 12,791.00 | https://www.sec.gov/Archives/edgar/data/1137883/000110465920021983/0001104659-20-021983-index.htm | ||
| 2020-07-10 | International Holdings Ltd. ACC | Insider | Sell | 2,000.00 | 13.35 | 26,700.00 | 133,306.00 | https://www.sec.gov/Archives/edgar/data/1137883/000110465920084119/0001104659-20-084119-index.htm |
| 2020-07-09 | International Holdings Ltd. ACC | Insider | Sell | 3,500.00 | 13.13 | 45,938.55 | 135,306.00 | https://www.sec.gov/Archives/edgar/data/1137883/000110465920084119/0001104659-20-084119-index.htm |
| 2020-03-06 | Ralph Dr. Kern | COO and Chief Medical Officer | Buy | 35,885.00 | 151,540.00 | https://www.sec.gov/Archives/edgar/data/1137883/000110465920030195/0001104659-20-030195-index.htm | ||
| 2017-08-31 | IRIT ARBEL | Director | Buy | 2,500.00 | 4.26 | 10,650.00 | 155,833.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420417046175/0001144204-17-046175-index.htm |
| 2019-08-28 | IRIT ARBEL | Director | Sell | 13,332.00 | 3.67 | 48,891.11 | 155,833.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420419043047/0001144204-19-043047-index.htm |
| 2020-02-01 | Anthony J. Polverino | Director | Buy | 3,071.00 | 15,862.00 | https://www.sec.gov/Archives/edgar/data/1137883/000110465920021983/0001104659-20-021983-index.htm | ||
| 2019-08-28 | IRIT ARBEL | Director | Buy | 6,666.00 | 2.25 | 14,998.50 | 162,499.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420419043047/0001144204-19-043047-index.htm |
| 2019-08-28 | IRIT ARBEL | Director | Buy | 6,666.00 | 2.25 | 14,998.50 | 169,165.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420419043047/0001144204-19-043047-index.htm |
| 2020-06-23 | Uri Yablonka | EVP & Chief Business Officer | Buy | 10,000.00 | 17,543.00 | https://www.sec.gov/Archives/edgar/data/1137883/000110465920077512/0001104659-20-077512-index.htm | ||
| 2019-12-12 | June Sherie Almenoff | Director | Buy | 2,000.00 | 2,000.00 | https://www.sec.gov/Archives/edgar/data/1137883/000110465920021982/0001104659-20-021982-index.htm | ||
| 2017-07-26 | Chaim Lebovits | Officer | Buy | 31,185.00 | 2,103,785.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420417038410/0001144204-17-038410-index.htm | ||
| 2018-07-26 | Chaim Lebovits | Officer | Buy | 31,185.00 | 2,134,970.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420418040473/0001144204-18-040473-index.htm | ||
| 2020-07-15 | Sankesh Abbhi | Director | Buy | 46,779.00 | 12.99 | 607,659.21 | 2,164,530.00 | https://www.sec.gov/Archives/edgar/data/1137883/000110465920084127/0001104659-20-084127-index.htm |
| 2019-07-26 | Chaim Lebovits | Officer | Buy | 31,185.00 | 2,166,155.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420419036266/0001144204-19-036266-index.htm | ||
| 2017-11-20 | Eyal Rubin | CFO and Treasurer | Buy | 25,000.00 | 25,000.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420417060168/0001144204-17-060168-index.htm | ||
| 2019-09-06 | Preetam Shah | EVP, CFO and Treasurer | Buy | 25,000.00 | 25,000.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420419043864/0001144204-19-043864-index.htm | ||
| 2020-06-01 | Stacy Lindborg | EVP, Head Global Clin Research | Buy | 25,000.00 | 25,000.00 | https://www.sec.gov/Archives/edgar/data/1137883/000110465920068501/0001104659-20-068501-index.htm | ||
| 2017-11-10 | MALCOLM S TAUB | Director | Buy | 12,000.00 | 29,332.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420417058398/0001144204-17-058398-index.htm | ||
| 2020-09-08 | Anthony Waclawski | Officer | Buy | 35,000.00 | 35,000.00 | https://www.sec.gov/Archives/edgar/data/1137883/000110465920103943/0001104659-20-103943-index.htm | ||
| 2018-02-01 | Anthony J. Polverino | Director | Buy | 3,623.00 | 3,623.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420418005728/0001144204-18-005728-index.htm | ||
| 2019-12-24 | Preetam Shah | EVP, CFO and Treasurer | Buy | 11,600.00 | 3.96 | 45,929.04 | 36,600.00 | https://www.sec.gov/Archives/edgar/data/1137883/000110465919076290/0001104659-19-076290-index.htm |
| 2018-03-15 | Ralph Dr. Kern | COO and Chief Medical Officer | Buy | 5,000.00 | 3.60 | 17,997.00 | 40,885.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420418015580/0001144204-18-015580-index.htm |
| 2018-11-30 | MALCOLM S TAUB | Director | Buy | 12,000.00 | 41,332.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420418062649/0001144204-18-062649-index.htm | ||
| 2017-11-10 | ROBERT G L SHORR | Director | Buy | 8,666.00 | 45,731.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420417058402/0001144204-17-058402-index.htm | ||
| 2020-04-06 | Sankesh Abbhi | Director | Buy | 4,657.00 | 4,657.00 | https://www.sec.gov/Archives/edgar/data/1137883/000110465920044267/0001104659-20-044267-index.htm | ||
| 2020-04-07 | David Setboun | EVP and COO | Buy | 50,000.00 | 50,000.00 | https://www.sec.gov/Archives/edgar/data/1137883/000110465920044272/0001104659-20-044272-index.htm | ||
| 2019-12-12 | MALCOLM S TAUB | Director | Buy | 12,000.00 | 53,332.00 | https://www.sec.gov/Archives/edgar/data/1137883/000110465920021981/0001104659-20-021981-index.htm | ||
| 2020-07-16 | David Setboun | EVP and COO | Buy | 5,000.00 | 12.95 | 64,740.00 | 55,000.00 | https://www.sec.gov/Archives/edgar/data/1137883/000110465920084123/0001104659-20-084123-index.htm |
| 2018-08-28 | Arturo Araya | Chief Commercial Officer | Sell | 2,805.00 | 5,608.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420418047847/0001144204-18-047847-index.htm | ||
| 2018-11-30 | Anthony J. Polverino | Director | Buy | 2,000.00 | 5,623.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420418062654/0001144204-18-062654-index.htm | ||
| 2018-03-15 | June Sherie Almenoff | Director | Buy | 5,700.00 | 3.50 | 19,950.00 | 5,700.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420418015059/0001144204-18-015059-index.htm |
| 2020-07-16 | International Holdings Ltd. ACC | Insider | Sell | 7,823.00 | 13.47 | 105,350.78 | 67,053.00 | https://www.sec.gov/Archives/edgar/data/1137883/000110465920084119/0001104659-20-084119-index.htm |
| 2018-02-26 | Arturo Araya | Director | Buy | 4,152.00 | 7,164.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420418011819/0001144204-18-011819-index.htm | ||
| 2019-01-04 | June Sherie Almenoff | Director | Buy | 1,475.00 | 3.39 | 5,000.25 | 7,175.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420419000986/0001144204-19-000986-index.htm |
| 2018-11-30 | Anthony J. Polverino | Director | Buy | 1,667.00 | 7,290.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420418062654/0001144204-18-062654-index.htm | ||
| 2020-07-15 | International Holdings Ltd. ACC | Insider | Sell | 18,430.00 | 13.12 | 241,714.98 | 74,876.00 | https://www.sec.gov/Archives/edgar/data/1137883/000110465920084119/0001104659-20-084119-index.htm |
| 2017-08-23 | Uri Yablonka | EVP & Chief Business Officer | Buy | 2,000.00 | 3.98 | 7,960.00 | 7,543.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420417044724/0001144204-17-044724-index.htm |
| 2018-03-06 | Ralph Dr. Kern | COO and Chief Medical Officer | Buy | 35,885.00 | 76,770.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420418016910/0001144204-18-016910-index.htm | ||
| 2018-03-26 | Arturo Araya | Director | Buy | 1,249.00 | 8,413.00 | https://www.sec.gov/Archives/edgar/data/1137883/000114420418016909/0001144204-18-016909-index.htm | ||
| 2019-12-24 | Arturo Araya | Chief Commercial Officer | Buy | 3,000.00 | 3.90 | 11,700.00 | 8,608.00 | https://www.sec.gov/Archives/edgar/data/1137883/000110465919076289/0001104659-19-076289-index.htm |
| 2020-07-13 | International Holdings Ltd. ACC | Insider | Sell | 40,000.00 | 13.52 | 540,952.00 | 93,306.00 | https://www.sec.gov/Archives/edgar/data/1137883/000110465920084119/0001104659-20-084119-index.htm |